Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study
Can-Fite BioPharma reports longer survival in its Phase 3 liver cancer trial and raises $4 million through a warrant exercise.
Stocks · News reference
Can-Fite Says Blinded Overall Survival Observed Across Entire Patient Population In Ongoing Pivotal Phase III Study Of Namodenoson In Advanced HCC Appears Longer Than Originally Anticipated Based On Assumptions Underlying Study Design
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Can-Fite BioPharma shares are trading lower after the company said blinded overall survival in its Phase III Namodenoson study for advanced HCC appears longer than expected under the trial design assumptions.
Can-Fite BioPharma To Receive ~$4M From Exercise Of 1,591,738 Warrants At Reduced $2.50/ADS Price
Can-Fite Plans To Advance Interim Analysis Of Phase III Namodenoson Study In Advanced Hepatocellular Carcinoma